Pancreatic Cancer Research

ResearcherUniversity of KochiActive in the last 2 years

Sunao Uemura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7299-0152; OpenAlex author ID A5087813406. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 7 papers

Papers 10

  1. Does Recurrent Pancreatic Cancer Have Similar Outcomes Compared With Primary Metastatic Pancreatic Cancer? Co-author DOI 10.1002/jso.70222↗
  2. Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology. Co-author DOI 10.1007/s11033-026-12767-x↗
  3. Nutritional Therapy in Pancreatic Cancer: Mechanisms, Clinical Applications, and Future Perspectives. Co-author DOI 10.1080/01635581.2026.2698777↗
  4. Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy. Co-author DOI 10.1080/07357907.2026.2703787↗
  5. Precision Pancreatic Cancer Care: From Early Detection to Adaptive Precision Oncology. Co-author DOI 10.1080/07357907.2026.2721529↗
  6. Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection. Co-author DOI 10.1080/14737140.2026.2709779↗
  7. Revisiting chronic pancreatitis as a risk factor for pancreatic ductal adenocarcinoma: toward precision risk stratification. Co-author DOI 10.1080/17474124.2026.2750981↗
  8. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell car… Co-author DOI 10.1016/j.neo.2021.07.006↗
  9. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0335↗
  10. Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation. Co-author DOI 10.1007/s10689-017-0025-7↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takehiro Okabayashi · 7 shared papers, 2026 · strength 2.61
  2. Shuta Tamura · 7 shared papers, 2026 · strength 2.61
  3. Jun Iwata · 1 shared paper, 2026 · strength 0.29
  4. Manabu Matsumoto · 1 shared paper, 2026 · strength 0.29
  5. Tatsuo Iiyama · 1 shared paper, 2026 · strength 0.29
  6. Shinya Sakamoto · 1 shared paper, 2026 · strength 0.29
  7. Shigehiro Tsujii · 2 shared papers, 2021 · strength 0.25
  8. Tetsuji Naka · 2 shared papers, 2021 · strength 0.25
  9. Kazuhiro Hanazaki · 2 shared papers, 2021 · strength 0.25
  10. Eri Munekage · 1 shared paper, 2021 · strength 0.11
  11. Yoshimi Kiyozumi · 1 shared paper, 2018 · strength 0.08
  12. Kenichi Urakami · 1 shared paper, 2018 · strength 0.08
  13. Ken Yamaguchi · 1 shared paper, 2018 · strength 0.08
  14. Katsuhiko Uesaka · 1 shared paper, 2018 · strength 0.08
  15. Hiroyuki Matsubayashi · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.